£20 Million Drug Development Centre - Cancer Research UK

Main Category: Cancer / Oncology
Article Date: 25 Oct 2007 - 13:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:not yet rated

Healthcare Prof:not yet rated


A state-of-the-art facility devoted to developing experimental cancer treatments is to be built at Cancer Research UK's Clare Hall Laboratories in Hertfordshire, helping to bring the latest scientific developments to patients' bedsides.

The purpose-built facility - which will cost a total of £20 million to build and equip - will house Cancer Research UK's Biotherapeutics Development Unit (BDU), responsible for developing antibodies, gene therapies and cancer vaccines for use in clinical trials.

The facility plays a crucial role in producing new biological therapies, which will be tested in early clinical trials through the charity's Drug Development Office. If successful, they could one day be used to treat cancer patients, helping turn scientists' discoveries into potentially life-saving treatments.

Biological therapies are developed from natural substances in the body. They fight cancer by either specifically targeting cancer cells, encouraging the body's immune system to attack the cancer or by preventing abnormal genes from working.

The new facility, which will house £3.5 million-worth of new equipment and employ 15 staff, will significantly increase the number of biological treatments produced by Cancer Research UK for testing in humans.

Building work has already begun at the site, with the facility scheduled for completion in May 2009.

Gillian Lewis, the head of Cancer Research UK's Biotherapeutics Development Unit, said: "The new facility is a hugely exciting development for the charity, giving us a building designed specifically for the BDU from the inside out.

"Biotherapeutics really are at the cutting edge in terms of the development of new cancer treatments, and in order to achieve significant advances we need the best facilities. That's exactly what the new building gives us."

Harpal Kumar, Cancer Research UK's chief executive added: "Bridging the gap between the bench and the bedside is especially challenging in the development of biological treatments, with a great deal of work necessary before new treatments can be used in clinical trials.

"Ensuring that patients continue to benefit from the latest research into cancer treatments is crucial for the charity. The new BDU facility a vitally important development in making this happen."

An artist's impression of the new facility is available for publication.

Cancer Research UK is a European leader in the development of new treatments for cancer.

We have taken over 100 potential new treatments from the lab and into clinical trials in patients. Four of these have reached the market and many more are still at different stages of development.

Visit our patient information website CancerHelp UK for more information on biological therapy.

About the BDU

The BDU is responsible for the manufacture of clinical grade biological products and forms part of Cancer Research UK's Drug Development Office. The unit is run to current Good Manufacturing Practice (cGMP) and has a license issued by the Medicines and Healthcare Products Regulatory Agency (MHRA) for the manufacture of investigational medicinal products (IMPs).

The BDU has the capability of manufacturing plasmid DNA, monoclonal antibodies and recombinant proteins. Its development team has extensive experience in the optimisation and scale up of manufacturing protocols and provides the necessary assay development. The Quality Control (QC) department carries out all the required quality control testing to ensure the quality, safety and efficacy of the product.

About Cancer Research UK

- Together with its partners and supporters, Cancer Research UK's vision is to beat cancer.
- Cancer Research UK carries out world-class research to improve understanding of the disease and find out how to prevent, diagnose and treat different kinds of cancer.
- Cancer Research UK ensures that its findings are used to improve the lives of all cancer patients.
- Cancer Research UK helps people to understand cancer, the progress that is being made and the choices each person can make.
- Cancer Research UK works in partnership with others to achieve the greatest impact in the global fight against cancer.

http://www.cancerresearchuk.org

Article adapted by Medical News Today from original press release.
Visit our cancer / oncology section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Cancer Research UK. "£20 Million Drug Development Centre - Cancer Research UK." Medical News Today. MediLexicon, Intl., 25 Oct. 2007. Web.
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/86711.php>

APA
Cancer Research UK. (2007, October 25). "£20 Million Drug Development Centre - Cancer Research UK." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/86711.php.

Please note: If no author information is provided, the source is cited instead.


Cancer / Oncology

What is Cancer?

Cancer is a class of diseases characterized by out-of-control cell growth. There are over 100 different types of cancer, and each is classified by the type of cell that is initially affected. Read more...

Most Popular Articles



Follow Our Cancer News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Cancer / Oncology Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »